Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 13.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,584 shares of the company’s stock after selling 8,136 shares during the quarter. ProShare Advisors LLC’s holdings in Roivant Sciences were worth $646,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $39,000. PNC Financial Services Group Inc. increased its holdings in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company’s stock valued at $89,000 after acquiring an additional 3,426 shares during the period. Finally, Blue Trust Inc. increased its holdings in shares of Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after acquiring an additional 6,667 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the business’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Venker sold 434,478 shares of the business’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the sale, the chief operating officer now owns 1,127,290 shares in the company, valued at $12,197,277.80. The trade was a 27.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,223,959 shares of company stock valued at $13,450,035. 7.90% of the stock is owned by company insiders.

Roivant Sciences Stock Performance

Shares of ROIV opened at $10.87 on Friday. The stock has a market capitalization of $7.76 billion, a P/E ratio of -72.46 and a beta of 1.23. The company’s fifty day moving average is $10.53 and its two-hundred day moving average is $11.05. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.